E 602 News Today

Increasing knowledge of the cancer glycome and the need for new options to overcome resistance to immune checkpoint inhibitors are leading to an expansion of glycoimmunology. Stanford University professor Carolyn Bertozzi demonstrated that cell-surface glycans may be tagged to become targetable glyco-immune checkpoints.

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed - Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights - Palleon receives upfront payment and is eligible for up to $196.5 million in milestone payments - SHANGHAI, June 28, 2022 /PRNewswire/ --Palleon Pharmaceuticals Inc., a companypioneering the field of glyco-immunology to treat cancer...